Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Leukemia & Lymphoma
Volume 63, 2022 - Issue 3
Letters to the Editor
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression
Tina Roya Division of Hematology and Oncology Georgetown University School of Medicine Washington, DC, USACorrespondence[email protected]
https://orcid.org/0000-0001-9065-7601
https://orcid.org/0000-0001-9065-7601, , , & David H. Vesolea Division of Hematology and Oncology Georgetown University School of Medicine Washington, DC, USA;b Myeloma Division, John Theurer Cancer Center at Hackensack Meridian School of Medicine Hackensack, NJhttps://orcid.org/0000-0001-7721-3870
https://orcid.org/0000-0001-7721-3870![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})